Biotech
CRISPR Therapeutics
CRISPR Therapeutics develops gene-based medicines using CRISPR/Cas9 editing, co-founded on foundational work by Emmanuelle Charpentier. Its lead therapy for sickle cell disease emerged from research partnerships spanning ETH Zurich and leading hematology centers.
$0.7B R&D Spend
Biotech Industry
120 Academic Collaborations
900 Patents
Industry
Biotech →Researchers connected to CRISPR Therapeutics
Free to browse · subscribe to unlock the full dataset
See the full dataset.
Create a free account to search every researcher, set alerts, and export verified contacts to CSV / API.
Sign Up Free →